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SUMMARY
In the Netherlands a strong epidemic outbreak of pertussis took place in 1996–7. Here we
investigate the possible causes of the epidemic, using an age-structured epidemic model.
Motivated by the observation that during the epidemic the number of cases in vaccinated
children had increased considerably compared to the preceding period, we focus on two
vaccination related changes. First, we consider the possibility that the potency of the vaccine
decreased so that it confers protection for a shorter period of time in newly vaccinated
children. Second, we consider the possibility that at a certain point in time the duration of
protection after vaccination decreased for all individuals. This may be the case if the pathogen
population changed such that the current vaccine confers less protection. A comparison of the
observed and simulated age-distribution of infections indicates that the second scenario is more
in line with the observed pattern of the 1996–7 epidemic. We discuss the implications of this
conclusion for B. pertussis circulation, and for the design of vaccination programmes in the
face of a polymorphic B. pertussis population that may adapt itself to vaccination.
INTRODUCTION
Pertussis (whooping cough) is a highly infectious
disease of the upper respiratory tract. Before the
introduction of vaccination pertussis was one of the
main causes of child morbidity in developed countries.
After the introduction of mass vaccination the
incidence of pertussis decreased to very low levels in
the sixties and seventies. However, in the last 15 years
there has been a resurgence of pertussis in many
developed countries (e.g. Canada [1], USA [2–4], UK
[5]).
In the Netherlands a strong epidemic outbreak of
pertussis was observed in 1996–7 [6, 7] ; while the
general incidence of pertussis according to notification
* Author for correspondence, present address : Institute for Animal
Science and Health, PO Box 65, 8200 AB Lelystad, the Netherlands.
data was very low from 1988 up to 1995, less than
three cases per 100000, it increased more than tenfold
in 1996 and 1997.
To illustrate this, Figure 1 shows the age-specific
incidence of reported cases of pertussis according to
notifications in the Netherlands in the pre-epidemic
period (1988–95), and in the 1996–7 epidemic. The
distributions show a distinctive pattern. The incidence
is high in predominantly unvaccinated infants under 1
year of age. It is much lower in the age-classes of 1–3
years, and it reaches a second peak at 4 years of age.
The figure also shows a clear-cut difference between
the pre-epidemic and epidemic period. While the total
incidence according to notifications increased more
than tenfold in 1996–7, the incidence in newborns
(! 1 year) increased only about fourfold. As a result,
the fraction of notified cases in newborns decreased
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Fig. 1. Age-specific incidence of notified pertussis cases in
the Netherlands. Panel (a) shows the distribution from 1988
up to 1995 (before the epidemic), while panel (b) shows the
age distribution in 1996 and 1997 (during the epidemic) see
[6] for details.
from 19% in the 1988–95 period to just 6% in 1996–7
[6].
Vaccination against pertussis is given in the first
year of life. Four doses of whole-cell vaccine are
administered at 3, 4, 5, and 11 months of age.
Vaccination coverage in the Netherlands has been
high ever since the introduction of the Dutch
vaccination programme in 1953. In fact, the fraction
of the population that is vaccinated has been about
96% over the years, while since 1976 the vaccination
coverage has not fallen below 95% in any yearly
cohort. Furthermore, the intrinsic quality of the
Dutch vaccine is measured for each vaccine batch by
the National Institute of Public Health and the
Environment (RIVM), and meets international stan-
dards.
Nevertheless, a close analysis of the notified cases
shows that a surprisingly large number of symp-
tomatic infections took place in vaccinated infants in
1996–7 as compared to the 1988–95 period [6, 7]. In
fact, in these years the incidence based on notifications
was quite comparable in the vaccinated and
unvaccinated populations of 4 years and older. This
indicates that protection against infection after vac-
cination does not last lifelong [8–10].
We see two possible explanations for the sudden
increase of pertussis in vaccinated children. First, it
may be that the effectiveness of the vaccine decreased
so that it confers immunity for a shorter period of
time. In this case, one would expect that only cohorts
vaccinated with the less effective vaccine are affected.
Although the Dutch whole-cell vaccine meets in-
ternational standards, noticeable differences between
vaccine batches are sometimes observed [11–13].
Second, it has been shown that the composition of the
B. pertussis population has changed, resulting in a
possible mismatch with the currently used vaccine
[14, 15]. In that case, one would expect that all
vaccinated cohorts are affected more or less equally.
In this paper we evaluate, by means of an age-
structured epidemic model, the above mentioned
hypotheses for the 1996–7 epidemic and the increased
incidence in vaccinated infants. We present a model
that makes a distinction between infection in immuno-
logically naive individuals, and infection after vac-
cination or infection. Throughout we include the
possibility that immunity is lost at a certain small rate.
The 1988–95 incidence data are used to estimate the
so-called force of infection (the probability that a
susceptible is infected in a time-period) in the pre-
epidemic period. The method that is used is based on
the underlying dynamic model, and takes into account
sub-clinical infection and waning of immunity in a
consistent manner [16]. Other parameters are taken
from the literature, or represent educated guesses.
The analysis reveals that the second scenario, which
implies a decrease in the period of immunity after
vaccination for all age-classes leads to results that are
more in line with the observed age-distribution of
pertussis in the Netherlands in 1996–7. For this
scenario already a slight increase in the rate at which
immunity is lost after vaccination is sufficient to
produce a sizeable epidemic if most adults were
protected by vaccination in the pre-epidemic period.
METHODS AND MODEL STRUCTURE
Model structure
The main features of our model are (1) that it
distinguishes between immunity conferred by vac-
cination or infection; and (2) that it makes a
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Fig. 2. Schematic structure of the model. See text for
details.
distinction between infection in immunologically
naive individuals (henceforth called primary infec-
tion), and infection in individuals whose immune
system has been primed by infection or vaccination
(secondary infection). We denote by S
"
the relative
frequency of immune naive individuals. Likewise, S
#
denotes the relative frequency of susceptible indi-
viduals whose immune system has been primed before.
I
"
and I
#
denote the relative frequencies of individuals
with primary and secondary infection, respectively
(i.e. infected from the immunologically naive or
immunologically primed state). V denotes the relative
frequency of individuals protected against infection
after vaccination, and R gives the relative frequency of
individuals protected after natural infection. All
variables are age- and time-dependent. Figure 2 gives
a schematic structure of the model.
Throughout this paper we assume that the mortality
rate is zero up to the age of Lfl 75 years, and that 75
years is also the maximum life span, i.e. everyone dies
exactly at that age. This type of mortality is a
reasonable approximation for the mortality rate in
developed countries [17]. Furthermore, we assume
that deaths are exactly balanced by births, so that
total population size is kept constant. All newborns
enter the population in the susceptible class S
"
.
The rates at which a primary or secondary infection
is cleared are assumed to be constant, and are denoted
by q
"
and q
#
, respectively. Hence, the mean infectious
periods are given by 1}q
"
and 1}q
#
. The constant rates
at which immunity after infection or vaccination is
lost are denoted by r
I
and r
V
, respectively. In view of
the absence of quantitative data, we assume that
secondary infections have a fixed ratio of
infectiousness relative to primary infections (b
#
}b
"
).
The age-dependent vaccination function is given by
m(a), and the age- and time-dependent rate at which
susceptibles acquire infection (the force of infection)
by k(a, t). The equations governing the dynamics of
the model, and a brief outline on the estimation
method for the force of infection are given in the
Appendix.
Model parameters
For most parameters reliable estimates are virtually
absent. They are therefore taken in accordance with
other modelling studies [16, 19–21], or represent
educated guesses. For instance, although it is known
that the vaccine may not lead to effective immunity in
all vaccinated individuals (i.e. primary vaccine fail-
ure), quantitative data is lacking. Here we assumed
that 85% of the population is effectively vaccinated at
one year of age. In view of the fact that 96% of the
population is vaccinated, this means that the vaccine
takes in almost 89% of the vaccinated individuals.
Furthermore, although it seems plausible that primary
and secondary infections may differ in some of their
characteristics (e.g., infectiousness, infectious period),
there is a conspicuous lack of quantitative infor-
mation. We assumed that primary infections are five
times more infectious than secondary infections (b
#
}b
"
fl 0–2), and that the infectious period is about 2 weeks
for both types of infection. An overview of the various
parameters and their default values except those
describing the contact function is given in Table 1.
Reliable estimates of the force of infection are
particularly difficult to obtain. Typically, the force of
infection will depend on population density, on
population structure, on the number of contacts
between individuals in a population, on the type of
contacts, etc. It is therefore questionable whether
estimates of the force of infection obtained in one
population at a certain moment in time give a
reasonable estimate for another population at another
moment in time. Our estimates of the force of infection
are obtained from the notification data of the
Netherlands in the pre-epidemic period (1988–95; see
Fig. 1) with the method developed in [16]. These
estimates are at least consistent with the dynamic
model (1). The force of infection so estimated depends
on the fraction of the population vaccinated, on the
duration of protection after vaccination in the pre-
epidemic period, and on the fractions p
"
and p
#
of
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Table 1. Oeriew of model parameters and their default alues. See Table
2 for scenarios
Description Parameter Value
Rate of loss of immunity
after infection
r
I
0–05 (yr−")
Rate of loss of immunity r
V
0–1 (yr−") (Scenario 1)
after vaccination (1998–95) 0 (yr−") (Scenario 2)
Rate of loss of immunity
after vaccination (1996–…)
r
V
0–2 (yr−") (both scenarios)
Rate of loss of primary infection q
"
25 (yr−")
Rate of loss of secondary
infection
q
#
25 (yr−")
Relative infectiousness of
secondary infection
b
#
}b
"
0–2
Fraction of susceptibles
effectively vaccinated
m 0–85
Age at vaccination tm 1 (yr)
Fraction of primary
infections that is notified
p
"
0–1
Fraction of secondary
infections that is notified
p
#
0–01
Table 2. Oeriew of the four scenarios. In Scenario
1 immunity after accination lasted for 10 years in
the pre-epidemic period (1988–95), and in Scenario 2
it lasted lifelong in the pre-epidemic period. In
Scenario A immunity after accination is reduced (to
5 years) for cohorts accinated after 1995 only, and
in Scenario B immunity after accination is reduced
for all cohorts
Scenario A Scenario B
Scenario 1 1998–1995: r
V
fl 0–1 1988–1995: r
V
fl 0–1
1996–2020: r
V
fl 0–2
for new cohorts
1996–2020: r
V
fl 0–2
for all cohorts
Scenario 2 1988–1995: r
V
fl 0 1988–1995: r
V
fl 0
1996–2020: r
V
fl 0–2
for new cohorts
1996–2020: r
V
fl 0–2
for all cohorts
primary and secondary infections that is notified. As
in our previous study [16] we assume that 1 out of 10
primary infections is notified (p
"
fl 0–1), and only 1
out of 100 secondary infections (p
#
fl 0–01). Although
these figures are not based on any comprehensive
research, they are not implausible for the situation in
the Netherlands, and they are compatible with other
studies [8, 9, 22–26].
Throughout this paper we will consider two
scenarios (labelled 1 and 2) with respect to the pre-
epidemic situation (1988–95), and two scenarios with
respect to the type of vaccination related change in the
population (labelled A and B). This gives four possible
combinations, 1A, 1B, 2A, and 2B. An overview of
the scenarios is given in Table 2.
In Scenario 1 we assume that immunity after
vaccination in the 1988–95 period lasted for 10 years
on average (r
V
fl 0–1), while in Scenario 2 we assume
that immunity after vaccination lasted lifelong in the
pre-epidemic period (r
V
fl 0). In view of the fact that
clinically recognized pertussis cases in vaccinated
individuals were rare but not absent in the pre-
epidemic period [6–7] the second scenario probably
overestimates the duration of protection by the
vaccine. Although the second scenario is not the most
realistic, it serves a useful purpose since it provides a
baseline against which the results of the first scenario
can be set. Estimates of the force of infection in the
pre-epidemic period (and hence on the contact
function and probabilities of infection) are given
below (Fig. 3; see [16] for methods).
With respect to the type of vaccination related
change, the scenarios A and B differ in the duration of
protection in cohorts vaccinated before 1996. In
Scenario A we assume that only for newly vaccinated
cohorts the duration of protection decreases to 5 years
on average (r
V
fl 0–2), while in Scenario B we assume
that all the duration of protection decreases to 5 years
for all vaccinated individuals. Scenario A applies to
the situation where the effectiveness of the vaccine
decreased, while Scenario B mimics the situation
where the pathogen population changed, resulting in
a mismatch with the vaccine.
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Fig. 3. Age-dependent force of infection as estimated from
the 1988–95 pertussis incidence data (see Fig. 1). The solid
circles show the force of infection if immunity after
vaccination lasted for 10 years in the pre-epidemic period
(Scenario 1), while open triangles show the force of infection
if immunity is assumed to have lasted lifelong in the pre-
epidemic period (Scenario 2).
RESULTS
The pre-epidemic period (1988–95)
Figure 3 gives the estimates of the force of infection
based on the notification data of the 1988–95 period
(Fig. 1). The solid circles show the results in case that
immunity after vaccination lasted 10 years in the pre-
epidemic period (Scenario 1), while the triangles show
the results in case that immunity lasted lifelong in the
pre-epidemic period (Scenario 2).
In both scenarios the force of infection is relatively
low in newborns (E 0–0032 (yr.−")). It then increases
to reach a peak in 5-year-old children of 0–008 in
Scenario 1 and of 0–0095 in Scenario 2. In the older
age-classes the force of infection decreases to low
values (! 2–5*10−% in Scenario 1, and ! 4–5*10−% in
Scenario 2). This means that the estimated probability
that a susceptible newborn is infected in a year is
about 0–32% (E 1fie−!–!!$#), that the probability that
a susceptible 5 year old is infected in a year is 0–8% in
Scenario 1 and 0–95% in Scenario 2, and that the
probability of adult infection is less than 0–025% in
Scenario 1 and less than 0–045% in Scenario 2.
Figure 4 shows the age-distribution of infecteds and
susceptibles 43 years after the introduction of mass
vaccination. Hence, the figure corresponds to the
situation in the Netherlands in 1995. Panels A
(Scenario 1) and C (Scenario 2) give the age-dependent
prevalence of the susceptible classes S
"
and S
#
, and the
infectious classes I
"
and I
#
, while panels B and D give
the corresponding incidence of infection. The preva-
lence of primary infection in newborns (which may
lead to severe complications) is relatively high, about
10 per 100000 individuals for both scenarios. Hence,
about 1 out of 10000 newborns will be infectious at
any given moment in time. The prevalence of primary
infection decreases to relatively low values (2 per
100000) just after vaccination, and it reaches a second
peak at 4 years of age (E 4 per 100000 in A; E 6 per
100000 in C). Note furthermore that in both scenarios
primary infections are extremely rare in individuals
older than 20 years of age.
Secondary infections typically do not lead to serious
disease. They may, however, play an important role in
keeping up circulation of B. pertussis. In Scenario 1
the majority of adults ("70%) are susceptible (S
#
) in
1995. As a result, the prevalence of secondary infection
might be within the range of measurement (" 0–1 per
100000, say) even though the force of infection on
adults is rather low. In Scenario 2, on the other hand,
the majority of adults (" 80%) is protected by
vaccination or by previous infection. As a result, the
prevalence of secondary infection is extremely low.
More specifically, in Scenario 1 the prevalence of
secondary infection reaches a peak of about 10 per
100000 in 6"
#
year old children, and is about 0–5 per
100000 in adults. In Scenario 2 the prevalence of
secondary infection is only non-negligible (E 0–5 per
100000) in unvaccinated adults over 43 years of age
who were born before the implementation of the
Dutch mass vaccination programme in 1953.
The age-specific incidences (in cases}100000}week)
as calculated from Figures 4A and 4C are given in
Figures 4B and 4D. Incidence is calculated as preva-
lence (I
i
(numbers per 100000)) divided by the infec-
tious period (1}q
i
) : "
&#
q
i
I *
i
(100000−" week−"). Note that
the figure gives the true incidence of infection rather
than the observed incidence throughnotification. Since
we assumed that 1 out of 10 primary infections is noti-
fied, and only 1 out of 100 secondary infections, the
observed incidence is readily obtained by multiplying
the true incidence of primary infection with "
"!
, the true
incidence of secondary infection with "
"!!
, and adding
up the resulting numbers. In Scenario 1 the incidence
of primary infection is only higher than the incidence
of secondary infection in the age-classes 0–2, From
age-class 3 onwards the true incidence of primary
infection is higher than the true incidence of secondary
infection. Hence, in these age-classes the majority
(" 95%) of infections is sub-clinical and remains
unnoticed. In Scenario 2, on the other hand, secondary
infections are almost absent.
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Fig. 4. The simulated situation of 1995, 43 years after the introduction of the Dutch vaccination programme. Panels (a)
(Scenario 1) and (c) (Scenario 2) show the simulated prevalences (in numbers per 100000) by age in case that immunity after
vaccination is assumed to last for 10 years and lifelong, respectively. Black lines denote the prevalence of infecteds (solid line :
I
"
; dashed line : I
#
), and grey lines denote the prevalence of susceptibles (solid line : S
"
; dashed line : S
#
). Note the logarithmic
scale on the ordinate. Panels (b) and (d ) show the corresponding incidence (in cases per 100000 per week) of primary infection
(black bars) and secondary infection (grey bars) by age.
With an interpretation of the pre-epidemic period
at hand, we proceed to investigate the consequences of
the two vaccination related changes mentioned above.
Scenario A: A decrease in vaccine effectiveness
First we investigate the consequences of a sudden
decrease in the period of protection conferred by the
vaccine in newly vaccinated infants only (Scenarios
1A and 2A). Table 3 and Figure 5 show the results.
Panels A and B of Figure 5 show time-plots of the
prevalence of primary and secondary infection for the
Scenarios 1A and 2A. The situation at tfl 0 in Panels
A and B corresponds, roughly, to 1995. Panels C and
D of Figure 5 show the age-specific incidence cor-
responding to panels A and B at the height of the first
epidemic peak.
Table 3. The contribution of infections in infants of
age zero as a fraction of the total number of
infections in the endemic situation ( f
endemic
), and at
the first epidemic peak ( f
epidemic
). See Table 2 for
oeriew of the scenarios, and the main text for
explanation
Pre-epidemic period First epidemic outbreak
Scenario 1: Scenario 1A: f
epidemic
fl 0–17
f
endemic
fl 0–17 Scenario 1B: f
epidemic
fl 0–15
Scenario 2: Scenario 2A: f
epidemic
fl 0–23
f
endemic
fl 0–29 Scenario 2B: f
epidemic
fl 0–18
As Figure 5 shows, a decrease in the duration of
protection provided by the vaccine leads to epidemic
outbreaks for both scenarios. The incidence of
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Fig. 5. Time plot of the total incidence as a function of time, and the age-specific incidence at the first epidemic peak after
a reduction in the period of immunity in newly vaccinated cohorts. Panels (a) and (c) shows the results for Scenario 1A
(immunity lasted for 10 years in the endemic period), while panels (b) and (d ) show the results for Scenario 2A (immunity lasted
lifelong in the endemic period). Panels (c) and (d ) give the simulated age-dependent incidence at the first epidemic peak (t
epidemic
fl 6–45 (yr.) in A; t
epidemic
fl 5–30 (yr.) in (b)). Note the difference in scale on the ordinate of panels (c) and (d ) in comparison
with Fig. 4.
primary and secondary infection ( "
&#
q
i
I *
i
(100000−"
week−")), which in the pre-epidemic period had
been 0–36 cases per 100000 per week, and 0–82
(100000−" week−") for Scenario 1 and 0–46 and 0–13 for
Scenario 2, increases to 4–6 and 12–0 at the height of
the first epidemic for Scenario 1, and even to 13–0 and
11–1 for Scenario 2.
The figure also shows that the first epidemic
outbreak occurs more than 5 years after the decrease
in vaccine effectiveness has taken place (after 6–45
years in A and 5–30 years in B). This is due to the fact
that the buildup of susceptibles is rather gradual. Only
if enough susceptible individuals in cohorts vaccinated
with the less effective vaccine have moved into those
age-classes that are at the highest risk of becoming
infected (1–7 years) is it possible that an epidemic may
occur.
Table 3 shows how the age-distribution of cases at
the height of the first epidemic peak is affected by a
decrease in the period of immunity conferred by the
vaccine. In particular, the table shows the contribution
of infections in newborns (infants of age zero) as
fraction ( f ) of all infections before and during the
epidemic. For Scenario 1 the relative contribution of
infections in infants of age zero does not change at all
( f
endemic
fl 0–17 versus f
epidemic
fl 0–17), while for Scen-
ario 2 the contribution of infection in newborns does
decrease to some extent ( f
endemic
fl 0–29 versus f
epidemic
fl 0–23). A discussion of this phenomenon is given
below.
Scenario B: A change in the pathogen population
Second, we considered a sudden decrease in the period
of immunity after vaccination for all cohorts
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Fig. 6. Time plot of the total incidence as a function of time, and the age-specific incidence at the first epidemic peak after
a reduction in the duration of immunity for all vaccinated individuals (see Fig. 5). Panels (a) and (c) show the results for
Scenario 1B (immunity lasted for 10 years in the endemic period), while panels (b) and (d ) show the results for Scenario 2B
(immunity lasted lifelong in the endemic period). Panels (c) and (d ) give the simulated age-dependent incidence at the first
epidemic peak (t
epidemic
fl 3–05 (yr.) in (a) ; t
epidemic
fl 1–70 (yr.) in (b)). Note the difference in scale on the ordinates in
comparison with Figures 4 and 5.
(Scenarios 1B and 2B). As before, the duration of
protection by vaccination is decreased from 10 years
in Scenario 1 (r
V
fl 0–1 (yr.−")) and lifelong in Scenario
2 (r
V
fl 0) to 5 years (r
V
fl 0–2). Table 3 and Figure 6
show the results.
Figure 6 shows that a change in the pathogen
population may in just a few years lead to strong
recurrent epidemics. This is especially so for Scenario
2 where we assumed that the vaccine conferred lifelong
immunity before the change in the pathogen popu-
lation. The incidence of primary and secondary
infection, which in the pre-epidemic period had been
0–36 and 0–82 cases per 100000 per week for Scenario
1, and 0–46 and 0–13 for Scenario 2, increases to 6–7
and 19–2 at the height of the first epidemic for
Scenario 1, and even to 33–2 and 52–9 for Scenario 2.
In the long run (E 50 years) the population reaches a
new endemic equilibrium that is at a considerably
higher level than in the 1988–95 period.
The age-distribution of infections shows another
striking difference between the two scenarios (Table
3). While for Scenario 1 the fraction of infections in
newborns only slightly decreases ( f
endemic
fl 0–17 to
f
epidemic
fl 0–16), for Scenario 2 the relative contrib-
ution of transmission to newborns decreases consider-
ably at the height of the first epidemic peak when
compared to the preceding endemic period ( f
endemic
fl
0–29 to f
epidemic
fl 0–18). This can be interpreted as
follows. For Scenario 1 the majority of adults was
already susceptible in the pre-epidemic period since
immunity after vaccination lasted for only 10 years on
average (Fig. 4). Hence, a decrease in the period of
protection provided by the vaccine will not increase
the number of susceptible adults greatly, and therefore
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cannot increase the number of infections in adults
considerably. This, however, is not so for Scenario 2
where in the pre-epidemic period most adults were
protected by vaccination. In fact, 85% of the
population is effectively vaccinated and will be
protected against infection for life. Hence, for this
scenario a decrease in the period of immunity after
vaccination does increase the prevalence of suscep-
tibles considerably and, as a consequence, also
increases the number of infections in adults.
DISCUSSION
A comparison of scenarios
The main aim of this paper was to compare two
vaccination related changes that may have accounted
for the pertussis epidemic in the Netherlands in
1996–7, and the strong increase in the number of cases
in vaccinated children [6, 7]. Our model results
indicate that a decrease in the duration of protection
by vaccination for all age-classes (corresponding to a
change in the pathogen population) will always lead
to a more pronounced epidemic than a decrease in the
duration of protection in newly vaccinated infants
only (corresponding to a change in the vaccine). This
is due to the fact that a change in the pathogen
population makes a potentially large reservoir of
adults previously protected by vaccination available
for infection in a short time-span (! 5 years, say). In
case of a change in the vaccine the pool of susceptibles
increases much slower because it is formed by
newborn cohorts that have been vaccinated with a less
effective vaccine. Also, it takes somewhat longer
before the threshold density of susceptibles is reached
that enables an epidemic to occur (5–7 years ; Fig. 5).
Furthermore, a comparison of the age-distributions
at the height of the first epidemic peak indicates that
a shift in the age-distribution of infections towards the
older age-classes is most likely to be observed if the
period of immunity provided by the vaccine is reduced
for all age-classes, and if the vaccine provided long-
lived protection in the pre-epidemic period. Again, the
reason is that a large reservoir of adults previously
protected by vaccination may become available for
infection in a relatively short time-span, therefore
shifting the balance towards the group of vaccinated
individuals.
The differences between the two vaccination related
changes considered here is more pronounced if a
larger fraction of the population was protected by
vaccination in the pre-epidemic period. Hence, the
differences between the two vaccination related
changes is larger if the rate at which immunity was lost
in the pre-epidemic period was low, and if the fraction
that was effectively vaccinated was high. If the vaccine
was already imperfect in the pre-epidemic period in
that it conferred immunity for a relatively short
period of time (e.g. 10 years ; Scenario 1), the difference
between the two scenarios in the age-distribution of
new infections will be rather small, and the epidemic
outbreaks will be modest. If the vaccine conferred
lifelong immunity in the pre-epidemic period (Scen-
ario 2), the differences between the age-distributions
age more pronounced, and the epidemic outbreaks are
much stronger.
Pertussis in the Netherlands
In the Netherlands the incidence of pertussis based on
notifications was low (less than 3 cases per year per
100000) in the pre-epidemic period (1988–95). It then
suddenly increased to more than 22 cases per year per
100000 in 1996 and 1997. In the pre-epidemic period
the incidence in vaccinated individuals was more than
an order of magnitude lower than the incidence in
unvaccinated individuals [7]. This indicates that the
Dutch Whole Cell Vaccine conferred protection
against severe disease for a prolonged period of time
in the pre-epidemic period. In 1996–7, on the other
hand, the incidence in the vaccinated and un-
vaccinated population of five years and older was
quite comparable. This indicates that the effectiveness
of the Dutch whole cell vaccine somehow decreased.
This is reflected by the unusually low estimates of
vaccine efficacy (based on notification data) as
estimated with the screening method in 1996–7 (! 0–3;
see [6, 7] for details, and [27, 28] for interpretation of
vaccine efficacy).
A close analysis of the age-distribution of cases in
the pre-epidemic and epidemic eras shows that the
incidence of pertussis based on notifications in
children of 3–9 years old was relatively low, about 10
per 100000 up to 1994, after which it increased to well
over 100 per 100000 in 1996 and 1997, a more than
tenfold increase [6, 7]. Equally strong relative in-
creases in incidence were observed in adolescents and
adults. In infants of age zero, on the other hand, the
relative increase in incidence in 1996–7 as compared
to 1988–95 was much less pronounced. In this age-
class the incidence increased from 32 cases per 100000
per year in 1988–95 to 117 cases per 100000 per year
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in 1995–6, a fourfold increase. As a result, the fraction
of all notified infections among infants less than 1 year
old decreased from 19% in 1988–95 to just 6% in
1996–7.
Model predictions versus observed pertussis incidence
Our model results indicate that a pronounced increase
of the incidence in older vaccinated children (more
than 5 years old, say) is very unlikely to be due to an
increased circulation in younger vaccinated children
less than 5 years old only. In fact, in our model we
only observed a noticeable decrease in the fraction of
infections in newborns if (1) the vast majority of
individuals were protected by vaccination in the pre-
epidemic period and if (2) the duration of the period of
protection after vaccination decreased for all indi-
viduals. We may conclude that, at least qualitatively,
the 1996–7 pertussis epidemic in the Netherlands is
most easily explained if the vaccine had high efficacy
in the pre-epidemic period (so that small changes in
vaccine efficacy already lead to sizeable epidemics),
and if there had been a change in the pathogen rather
than a change in the vaccine (so that a noticeable shift
in the age-distribution of cases towards older children
will be observed). Additional support for this view
comes from the fact that the shift in the age-
distribution of cases is mainly due to a strong increase
in the number of cases in vaccinated individuals,
rather than an increased circulation in unvaccinated
individuals of 1 year and older [6, 7].
Quantitatively, there are some distinct differences
between our model results and the 1996–7 pertussis
epidemic. First, the fraction of notified infections in
newborns decreased from 19% in the pre-epidemic
period to just 6% during the epidemic. In our model
the fraction of infections in newborns was just 17%
for Scenario 1, and almost 29% for Scenario 2. This
discrepancy with the observed fraction of infections in
newborns may be due to our procedure to estimate the
force of infection in the pre-epidemic period, to our
assumptions on the contact function (i.e. proportion-
ate mixing), and to uncertainties in model parameters
(e.g. infectiousness of primary versus secondary
infections, infectious period). However, varying the
ratio of the infectiousness of secondary versus primary
infections from 0–1 to 0–5, and the infectious period
from 1 to 3 weeks did not significantly affect the
results (M. van Boven, unpublished results). Most
importantly, we did not observe a decrease in the
fraction of infections newborns as pronounced as in
the data in any of the four model scenarios considered
here. This could be taken as prima facie evidence that
the decrease in the protected period after vaccination
may have been even stronger than considered here
(from lifelong to 5 years). This, however, is at odds
with the observation of waning of vaccine induced
immunity before 1995, and the continuous circulation
of B. pertussis before 1995 [6].
A variety of other factors may just as well account
for the discrepancy between empirical data and model
results. First and foremost, we assumed that the
change in the composition of the B. pertussis popu-
lation occurred very suddenly, at the end of 1995. This
is not very realistic. If the changes in the pathogen
population occur more gradually, the difference
between the scenarios are likely to become less
pronounced. Clearly, the present model is not suited
to answer the question how the effectiveness of the
vaccine changes over time, as arbitrary choices must
be made on the composition of the pathogen
population. To address this question, age-structured
models that explicitly include strain structure will
have to be considered.
Second, there may have been an increased aware-
ness of pertussis by the public and physicians. This
may have led to an increased probability that
secondary infections are recognized and notified at
present [c.f. 6, 7]. Furthermore, we assumed that the
degree of infectiousness, the probability of an in-
fection remaining sub-clinical, and the probability of
notification are not directly related to age. This is not
very plausible. Although it is generally assumed that
infections in newborns are more likely to be notified
than infections in adolescents and adults, there is at
present a conspicuous lack of reliable quantitative
information on this issue.
To address the question of the relation between age,
vaccination status, severity of an infection, and the
likelihood of notification, we are currently investi-
gating the immune status of the Dutch population at
large by analyzing pertussis specific IgA and IgG
antibody titers [29, 30], longitudinal trends in anti-
body titers in individual patients after a clinically
recognized infection, and by clinically assessing the
severity of B. pertussis infections in relation to age and
vaccination status. Together the results of these
analyses should give more insight in the relation
between the age and immune status of an individual,
the probability of infection, the probability of noti-
fication, and the severity of infection.
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Vaccination against an evolving B. pertussis
population
There is increasing molecular evidence that in com-
parison with the pre-vaccination era B. pertussis
strains circulating in the Netherlands have changed in
a number of virulence factors [14, 15]. A comparison
of the pertactin and pertussis toxin variants present in
the currently circulating strains of B. pertussis with the
variants present in the Dutch vaccine show that there
is at present a mismatch between the two. It is likely
that this mismatch has some adaptive significance.
In fact, there are indications that the older, ‘vaccine’
strain is found relatively more often in unvaccinated
individuals in comparison with the newly arising
strains [14]. This implies that the protection induced
by the vaccine appears to be less strong against the
new strains than it was against the vaccine strain.
Whether cross-immunity between the old and new B.
pertussis strains is also incomplete is at present not
known.
The fact that the B. pertussis population may have
evolved to circumvent the immune response elicited
by the vaccine raises a number of questions concerning
the composition and use of future vaccines like:
Which combination of antigens protects optimally
against the circulation strains? How should one
balance the breadth against the depth of a vaccine (i.e.
should one include many polymorphic antigens or
only a few monomorphic antigens)? Which vaccines,
vaccination schemes and coverages minimize the
probability of appearance of escape mutants? How
does the evolutionary pressure on the B. pertussis
population depend on the relationship between natu-
ral and vaccine-induced immunity? Should the aim of
vaccination be to reduce symptomatic disease while
maintaining circulation, or should it be to reduce the
infectiousness of the pathogen population? Such
evolutionary questions are just beginning to be
addressed by theoreticians and empiricists alike.
Careful confrontation of model predictions with real-
life data is the logical next step. The ultimate goal is,
of course, the application of the insights so obtained
to the development and use of future vaccines.
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APPENDIX : MODEL EQUATIONS AND
ANALYSIS
The dynamics of the model is given by the following
set of partial differential equations (PDEs) for the age-
and time-dependent variables :
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Total population size N(a, t) is given by the sum over
all variables. Hence,
¥N(a, t)
¥t
›
¥N(a, t)
¥a
flfil(a)N(a, t).
Since all individuals are born susceptible, and since we
assume that total population size remains constant,
this implies that the only non-trivial boundary
condition should satisfy
S
"
(0, t)fl&L
!
l(a)N(a, t) da,
i.e. deaths are exactly balanced by births.
The age- and time-dependent force of infection
k(a, t) is given by
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!
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Here the contact function c(a, a«) is a measure for the
number of contacts that an infected individual of age
a« makes with a susceptible individual of age a, while
the parameters b
"
and b
#
are the probability of
transmission in a contact of a susceptible individual
with a primary and secondary infected individual,
respectively.
To determine the force of infection, it is assumed
that the population is in the endemic equilibrium in
the 1988–95 period. As a consequence, the force of
infection is time-independent in this period (i.e. k(a, t)
flk(a)), and can be estimated using the endemic
equilibrium of the model (A1) and the incidence data
of Figure 1 [16]. Subsequently, given some assump-
tions on the form of the contact function, the force
of infection in the pre-epidemic period can be used to
obtain numerical estimates for the contact function
[18]. In the present study we made the particularly
simple assumption that the contact function has the
form c(a, a« )fl f (a) f (a« ). This is commonly referred
to as the ‘proportionate mixing’ assumption. There
are several reasons why one should not blindly trust
the numerical results obtained with the methods
outlined above. A strong point of the estimation
procedure of the force of infection is that estimates of
the force of infection are at least consistent with the
dynamical model (A1). We refer to van Boven et al.
[16] for a description of the procedure to estimate the
force of infection, and for a discussion of the pros and
cons of the method. General methods to estimate age-
specific forces of infection are presented in [31].
Hethcote [18] gives a clear account on the deter-
mination of the contact function from a given force
of infection.
In principle, various methods are available to
numerically integrate the PDEs (A1). However, in our
case the procedures are somewhat more complex than
usual, as the boundary condition S
"
(0, t) depends on
the variables through total population size N(a, t). To
address this complication, a specific method has been
developed, the so-called Escalator Boxcar Train. An
intuitive derivation is given in [32], while a formal
derivation is presented in [33].
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